The Pharmaletter

One To Watch

newamsterdam_company-1

NewAmsterdam Pharma

A Dutch clinical-stage company focused on the research and development of transformative therapies for cardio-metabolic diseases.

NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, as the preferred LDL-C lowering therapy to be used as an adjunct to maximally tolerated statin therapy for high-risk cardiovascular disease patients.

Want to Update your Company's Profile?


More NewAmsterdam Pharma news >